What do women with breast cancer expect from their treatment? Correlates of negative treatment expectations about endocrine therapy

Psycho-Oncology

Volumn 25, Issue 12, 2016, Pages 1485-1492

  Heisig, Sarah R ^a   Shedden Mora, Meike C ^a,b   von Blanckenburg, Pia ^c   Rief, Winfried ^c   Witzel, Isabell ^b   Albert, Ute Susann ^c,d   Nestoriuc, Yvonne ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d KRANKENHAUS NORDWEST   (Germany)

Author keywords

beliefs about medication; breast cancer; informed consent in oncology; necessity concern balance; nocebo; side effect expectations

Indexed keywords

AROMATASE INHIBITOR; HORMONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ADVERSE DRUG REACTION; AGED; ARTICLE; BELIEFS ABOUT MEDICINES QUESTIONNAIRE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DRUG SAFETY; EDUCATIONAL STATUS; FEMALE; HEALTH BELIEF; HUMAN; INTERVENTION STUDY; KNOWLEDGE; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOMATOSENSORY SYSTEM; TREATMENT RESPONSE; ADOLESCENT; BREAST TUMOR; CULTURAL ANTHROPOLOGY; MIDDLE AGED; NEOPLASM; NOCEBO EFFECT; PATIENT EDUCATION; PATIENT SATISFACTION; PSYCHOLOGY; STATISTICS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AROMATASE INHIBITORS; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; CULTURE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; NOCEBO EFFECT; PATIENT EDUCATION AS TOPIC; PATIENT SATISFACTION; STATISTICS AS TOPIC; SURVEYS AND QUESTIONNAIRES; TAMOXIFEN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959419694     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.4089     Document Type: Article

References (34)

1. Barsky AJ, Saintfort R, Rogers MP, Borus JF. Nonspecific medication side effects and the nocebo phenomenon. JAMA 2002;287:622–627. DOI:10.1001/jama.287.5.622.
2. Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J. Influence of context effects on health outcomes: a systematic review. Lancet 2001;357:757–762.
3. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999;47:555–567.
4. Nestoriuc Y, Schuricht F, von Blanckenburg P, Albert U-S, Rief W. Der Einfluss von Erwartungen auf den Behandlungsverlauf der Antihormonellen Therapie bei Brustkrebs-Patientinnen. [The influence of expectations on the course of endocrine therapy in patients with breast cancer.]. Verhaltenstherapie 2011;21:17.
5. Von Blanckenburg P, Schuricht F, Albert U-S, Rief W, Nestoriuc Y. Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: study protocol of a randomized controlled trial. BMC Cancer 2013;13:426. DOI:10.1186/1471-2407-13-426.
6. Nestoriuc Y, Orav EJ, Liang MH, Horne R, Barsky AJ. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care Res (Hoboken) 2010;62:791–799. DOI:10.1002/acr.20160.
7. Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients' adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the necessity-concerns framework. PLoS One 2013;8:e80633. DOI:10.1371/journal.pone.0080633.
8. Burstein HJ, Prestrud AA, Seidenfeld J, et al. American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010;28:3784–3796. DOI:10.1200/JCO.2009.26.3756.
9. The ATAC Trialists' Group. Comprehensive side effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633–643. DOI:10.1016/S1470-2045(06)70767-7.
10. Cluze C, Rey D, Huiart L, et al. Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Ann Oncol 2012;23:882–890. DOI:10.1093/annonc/mdr330.
11. Kirsch I. Response expectancy theory and application: a decennial review. Appl Prev Psychol 1997;6:69–79. DOI:10.1016/S0962-1849(05)80012-5.
12. Hofman M, Morrow GR, Roscoe JA, et al. Cancer patients' expectations of experiencing treatment-related side effects: a University of Rochester Cancer Center-community clinical oncology program study of 938 patients from community practices. Cancer 2004;101:851–857. DOI:10.1002/cncr.20423.
13. Schnur JB, Hallquist MN, Bovbjerg DH, Silverstein JH, Stojceska A, Montgomery GH. Predictors of expectancies for post-surgical pain and fatigue in breast cancer surgical patients. Pers Individ Dif 2007;42:419–429. DOI:10.1016/j.paid.2006.07.009.
14. Whitford HS, Olver IN. When expectations predict experience: the influence of psychological factors on chemotherapy toxicities. J Pain Symptom Manage 2012;43:1036–1050. DOI:10.1016/j.jpainsymman.2011.06.026.
15. Colagiuri B, Roscoe JA, Morrow GR, Atkins JN, Giguere JK, Colman LK. How do patient expectancies, quality of life, and postchemotherapy nausea interrelate? Cancer 2008;113:654–661. DOI:10.1002/cncr.23594.
16. Horne R. Treatment perceptions and self-regulation. In The Self-regulation of Health and Illness Behaviour, Cameron LD, Leventhal H (eds.), Routledge Taylor & Francis Group: London, 2003;138–153.
17. Horne R. Representations of medication and treatment: advances in theory and measurement. In Perceptions of Health and Illness: Current Research and Applications, Petrie KJ, Weinman J (eds.), Harwood academic publishers: London, 1997;155–188.
18. Heisig SR, Shedden-Mora MC, von Blanckenburg P, et al. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence. Psycho-Oncology 2015;24:130–137. DOI:10.1002/pon.3611.
19. Van Gülick-Bailer M, Maurer K, Häfner H. Schedules for Clinical Assessment in Neuropsychiatry Deutsche Ausgabe (SCAN), Göttingen, 1995.
20. Rief W, Barsky AJ, Glombiewski JA, Nestoriuc Y, Glaesmer H, Braehler E. Assessing general side effects in clinical trials: reference data from the general population. Pharmacoepidemiol Drug Saf 2011;20:405–415. DOI:10.1002/pds.2067.
21. Horne R, Weinman J, Hankins MM. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1–24. DOI:10.1080/08870449908407311.
22. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res 2006;60:631–637. DOI:10.1016/j.jpsychores.2005.10.020.
23. Barsky A, Wyshak G, Klerman G. The somatosensory amplification scale and its relationship to hypochondriasis. J Psychiatr Res 1990;24:323–334.
24. Herrmann-Lingen C, Buss U, Snaith RP. Hospital Anxiety and Depression Scale—Deutsche version (HADS-D). 3. Bern: 3; 2011.
25. Cosco TD, Doyle F, Ward M, McGee H. Latent structure of the Hospital Anxiety and Depression Scale: a 10-year systematic review. J Psychosom Res 2012;72:180–184. DOI:10.1016/j.jpsychores.2011.06.008.
26. Hinz A, Einenkel J, Briest S, Stolzenburg J-U, Papsdorf K, Singer S. Is it useful to calculate sum scores of the quality of life questionnaire EORTC QLQ-C30? Eur J Cancer Care (Engl) 2012;21:677–683. DOI:10.1111/j.1365-2354.2012.01367.
27. Schafer JL. NORM User's Guide (Version 2), The Methodology Center, PennState: University Park, 1999.
28. Costantini G, Epskamp S, Borsboom D, et al. State of the aRt personality research: a tutorial on network analysis of personality data in R. J Res Pers 2014. DOI:10.1016/j.jrp.2014.07.003.
29. Fruchterman TMJ, Reingold EM. Graph drawing by force-directed placement. Software Pract Ex 1991;21:1129–1164. DOI:10.1002/spe.4380211102.
30. Epskamp S, Cramer AOJ, Waldorp LJ, Schmittmann VD, Borsboom D. qgraph: network visualizations of relationships in psychometric data. J Stat Software 2012;48:1–18.
31. Laferton JAC, Auer CJ, Shedden-Mora MC, Moosdorf R, Rief W. Factors associated with disability expectations in patients undergoing heart surgery. Int J Behav Med 2015;22:85–91. DOI:10.1007/s12529-014-9434-2.
32. Bell RJ, Lijovic M, Fradkin P, et al. Lack of knowledge of hormone receptor status and use of endocrine therapy in invasive breast cancer. J Womens Health 2009;18:1975–1980. DOI:10.1089/jwh.2008.1351.
33. Boehm DU, Lebrecht A, Eckhardt T, et al. Quality of life and adjuvant tamoxifen treatment in breast cancer patients. Eur J Cancer Care (Engl) 2009;18:500–506. DOI:10.1111/j.1365-2354.2008.01015.x.
34. Fallowfield LJ, Cella D, Cuzick J, Francis S, Locker G, Howell A. Quality of life of postmenopausal women in the Arimidex, tamoxifen, alone or in combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 2004;22:4261–4271. DOI:10.1200/JCO.2004.08.029.